Arexvy s approval will help protect adults 60 years of age and older in Japan from RSV disease for the first time, including those living with underlying medical conditions who are.
GSK announced on Monday that its vaccine, Arexvy, has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for preventing respiratory syncytial virus (RSV) disease in adults aged 60 and over.
GSK plc (LSE/NYSE: GSK) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) for the prevention of RSV (respiratory syncytial virus) disease for adults 60 years of age and above. This is the first time an RSV .
GSK's Arexvy vaccine for RSV can remain effective against a range of variants and produces strong antibody responses against distinct viral strains.